Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
about
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenSelecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study.Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancerMammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.Analytical validation of a 12-gene molecular test for the prediction of distant recurrence in breast cancer.Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer?Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.High neuronatin (NNAT) expression is associated with poor outcome in breast cancer.Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.Spotlight on the utility of the Oncotype DX® breast cancer assay.Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among PhysiciansIdentifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine TherapyGenomic Testing in the Management of Early-Stage Breast CancerIntegration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
P2860
Q28077637-FDAB036F-85EB-4CE6-8EC1-9DD3131AEF18Q33834198-60DF1D3B-A8C4-4E6F-9856-7FDE4D8CD977Q33896397-F85C90DC-A8A8-483A-B98B-B02C7F83827AQ38635960-703EAA94-2087-423A-B48C-EED3B2EC04A7Q41012013-8594A12B-C6B0-4B69-B602-B28322C955ACQ41495744-97600EBE-30D6-47CA-8E06-CB8F1B850788Q41545259-4F16ACF2-6172-47CD-802A-A5C7C4F603E7Q41608998-BC43C713-4398-42FA-BDC0-1F25B64EB722Q41611004-E60F0A2C-371A-4BB9-BEE0-6B54DC57CE94Q47317337-5612EDD9-67B0-4679-B683-FBA445BE5FA2Q47372771-2072F704-717E-4303-99B5-79CCADB4E3D1Q48105586-796085DE-9FA5-4A9D-9091-AF97C28CFFB5Q48234773-994586B5-003D-45E0-BE7A-A1C835421FC8Q49951544-17D989BB-1849-4C45-9CC6-6557ECB50C0FQ52728983-C6F87ADF-56A2-43DB-9C21-29DEEEDC5835Q54987182-32B3D327-EB38-4207-B1EE-F0CD0983FA72Q56968394-FF798CF5-87FB-46E5-B9EB-10D6BDBA3605Q57116871-C67AF084-545D-45C3-8F82-38DFE14C5C97Q57117421-3961736E-B758-4315-82BB-88218FBCC157Q57178370-D5D16249-9426-4603-A5D9-DDADE1B0A539
P2860
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of EndoPredict and ...... rence After Endocrine Therapy.
@en
Comparison of EndoPredict and ...... rence After Endocrine Therapy.
@nl
type
label
Comparison of EndoPredict and ...... rence After Endocrine Therapy.
@en
Comparison of EndoPredict and ...... rence After Endocrine Therapy.
@nl
prefLabel
Comparison of EndoPredict and ...... rence After Endocrine Therapy.
@en
Comparison of EndoPredict and ...... rence After Endocrine Therapy.
@nl
P2093
P2860
P50
P356
P1476
Comparison of EndoPredict and ...... rrence After Endocrine Therapy
@en
P2093
Christoph Petry
Ivana Sestak
Jack Cuzick
Kristin Krappmann
Marsel Scheer
Peter Dubsky
Ralf Kronenwett
P2860
P356
10.1093/JNCI/DJW149
P407
P577
2016-07-10T00:00:00Z